Fluticasone Propionate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Maintenance treatment of asthma as prophylactic therapy | Adults and children ≥4 years (inhaled) | Controller monotherapy or with LABA | FDA Approved |
| Asthma in patients requiring oral corticosteroid therapy — oral steroid sparing | Adults and adolescents ≥12 years | Oral steroid replacement | FDA Approved |
Fluticasone propionate is among the most widely prescribed inhaled corticosteroids worldwide, with an extensive clinical evidence base spanning more than three decades since its initial US approval in 1994. As an ICS, it acts as an anti-inflammatory controller medication for asthma and is a cornerstone of current GINA and NAEPP treatment guidelines. Fluticasone propionate is distinguished from other ICS agents by its very high glucocorticoid receptor binding affinity, negligible oral bioavailability (<1%), and extensive first-pass hepatic metabolism, all of which contribute to a favourable ratio of local anti-inflammatory activity to systemic corticosteroid effects. It is available as a metered-dose inhaler (Flovent HFA and generics), dry powder inhaler (Flovent Diskus, ArmonAir Digihaler, Aermony RespiClick), and in fixed-dose combinations with salmeterol (Advair) and with umeclidinium and vilanterol (Trelegy Ellipta).
COPD (ICS component in triple or dual therapy): Evidence quality — High. GINA/GOLD guidelines support ICS use in COPD patients with eosinophilic phenotype (≥300 cells/μL) or frequent exacerbations, typically as part of ICS-LABA or ICS-LABA-LAMA triple therapy. Fluticasone propionate (alone or combined) has strong trial evidence from TORCH, ISOLDE, and IMPACT studies.
Eosinophilic oesophagitis (swallowed fluticasone): Evidence quality — Moderate. Fluticasone propionate MDI sprayed into the mouth and swallowed (without inhaling) is widely used off-label for eosinophilic oesophagitis, though purpose-built formulations are now available.
Dosing
Inhaled Dosing by Clinical Scenario (Flovent HFA / MDI)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild persistent asthma — ICS-naive, adults/adolescents ≥12 y | 88 mcg BID | 88 mcg BID | 880 mcg BID | 2 puffs of 44 mcg; titrate to lowest effective dose Maximum benefit may take 1–2 weeks |
| Moderate persistent asthma — inadequate on low-dose ICS, adults ≥12 y | 220 mcg BID | 220–440 mcg BID | 880 mcg BID | 1 puff of 220 mcg or 2 puffs of 110 mcg Consider step-up to ICS-LABA if not controlled at 440 mcg BID |
| Severe persistent asthma or oral steroid-dependent, adults ≥12 y | 440 mcg BID | 440–880 mcg BID | 880 mcg BID | 2 puffs of 220 mcg; wean oral prednisone by 2.5 mg/week Monitor for adrenal insufficiency during systemic steroid taper |
| Paediatric asthma — children 4–11 years | 88 mcg BID | 88 mcg BID | 88 mcg BID | 2 puffs of 44 mcg; higher doses not shown to provide additional benefit in this age group VHC with mask for children unable to coordinate MDI |
Fluticasone propionate is approximately twice as potent as beclomethasone dipropionate and budesonide on a microgram-for-microgram basis. GINA classifies fluticasone propionate doses in adults as low (100–250 mcg/day), medium (250–500 mcg/day), and high (>500 mcg/day). Always titrate to the lowest effective dose after achieving asthma control, typically stepping down after 3 months of stability. Patients should rinse their mouth with water and spit after each inhalation to reduce oropharyngeal candidiasis risk. When switching from systemic corticosteroids, taper prednisone by 2.5 mg per week while monitoring for adrenal insufficiency symptoms.
Pharmacology
Mechanism of Action
Fluticasone propionate is a synthetic trifluorinated glucocorticoid with potent anti-inflammatory activity. It binds to intracellular glucocorticoid receptors with high affinity (relative receptor affinity approximately 18 times that of dexamethasone), forming a steroid-receptor complex that translocates to the nucleus and modulates gene transcription. This results in suppression of multiple inflammatory mediators including cytokines (IL-4, IL-5, IL-13), chemokines, adhesion molecules, and inflammatory enzymes. At the airway level, fluticasone propionate reduces mucosal oedema, mucus hypersecretion, airway hyperresponsiveness, and eosinophilic infiltration. It also inhibits mast cell degranulation and dendritic cell antigen presentation. The clinical effect manifests as reduced asthma symptoms, improved lung function, and decreased exacerbation frequency, though maximum benefit may require 1–2 weeks of regular use.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability <1% (negligible GI absorption + extensive first-pass); inhaled systemic bioavailability ~13% (Diskus) to ~21% (pMDI); Tmax 1–2 h post-inhalation | Swallowed fraction contributes negligibly to systemic exposure; systemic effects arise almost entirely from lung-absorbed drug |
| Distribution | Vd 4.2 L/kg (~318 L); ~99% protein-bound; weakly and reversibly bound to erythrocytes | Large Vd indicates extensive tissue distribution; high protein binding limits free drug fraction |
| Metabolism | Extensive first-pass hepatic metabolism via CYP3A4 to inactive 17β-carboxylic acid metabolite; total clearance ~1.1 L/min (approaches hepatic blood flow) | Strong CYP3A4 inhibitors (ritonavir, ketoconazole) can markedly increase systemic exposure; contraindicated or use with extreme caution |
| Elimination | Primarily faecal excretion (parent + metabolites); <5% urinary; terminal t½ ~7.8 h | No renal dose adjustment needed; hepatic impairment may lead to drug accumulation |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Upper respiratory tract infection | 16–18% (vs 14% placebo) | Most common event; includes pharyngitis, nasopharyngitis; not necessarily drug-related |
| Headache | 5–11% (vs 6% placebo) | Dose-dependent (highest at low dose, 11% at 88 mcg BID); generally mild |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Throat irritation | 8–10% (vs 5% placebo) | Local effect of inhaled steroid; rinse mouth after use; use spacer if persistent |
| Sinusitis / sinus infection | 4–7% (vs 3% placebo) | Monitor for bacterial superinfection in patients with chronic sinusitis |
| Hoarseness / dysphonia | 2–6% (vs <1% placebo) | Dose-dependent; reversible on dose reduction; counsel voice professionals |
| Upper respiratory inflammation | 2–5% (vs 1% placebo) | Includes laryngitis and pharyngeal inflammation |
| Oral / pharyngeal candidiasis | 2–5% (vs <1% placebo) | Dose-dependent ICS class effect; mouth rinsing after each dose is essential prevention |
| Cough | 4–6% (vs 5% placebo) | May be related to propellant or powder irritation; distinguish from bronchospasm |
| Bronchitis | 2–6% (vs 5% placebo) | Generally not dose-related; may reflect underlying disease exacerbation |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| HPA axis suppression / adrenal crisis | Rare (dose-dependent) | Weeks to months at high doses | Morning cortisol or ACTH stimulation test; taper dose slowly; carry steroid emergency card if transitioning from systemic steroids |
| Growth suppression in children | Common at higher doses | Months; ~0.3–0.7 cm/year reduction in growth velocity | Monitor growth with regular stadiometry; use lowest effective dose; benefit of asthma control generally outweighs risk |
| Osteoporosis / decreased BMD | Uncommon (long-term, high dose) | Years of chronic use | Assess BMD risk factors; DEXA scan if indicated; calcium/vitamin D supplementation in high-risk patients |
| Glaucoma / posterior subcapsular cataracts | Uncommon (long-term) | Months to years | Ophthalmology referral for patients on long-term ICS or those with ocular symptoms; regular eye examinations |
| Anaphylaxis / immediate hypersensitivity | Very rare (postmarketing) | Minutes | Discontinue immediately; standard anaphylaxis management; permanent discontinuation |
| Paradoxical bronchospasm | Very rare | Immediately after inhalation | Treat with rescue SABA; discontinue fluticasone; switch to alternative ICS or device |
| Pneumonia (in COPD off-label use) | Increased risk (TORCH trial) | Weeks to months | Monitor for pneumonia in COPD patients on ICS; weigh exacerbation reduction benefit against pneumonia risk |
| Churg-Strauss syndrome (eosinophilic granulomatosis) | Very rare | During oral steroid taper | Evaluate for systemic eosinophilia, vasculitis, neuropathy; may require immunosuppressive therapy |
Oral candidiasis is the most clinically significant local adverse effect of inhaled fluticasone propionate. The incidence is dose-dependent (up to 5% at 440 mcg BID in clinical trials) and can be substantially reduced by instructing patients to rinse their mouth with water and spit after every inhalation. Using a spacer device with MDIs can also reduce oropharyngeal deposition. If candidiasis develops, treat with topical antifungal (nystatin suspension or clotrimazole troches) while continuing ICS therapy unless the infection is severe.
Drug Interactions
Fluticasone propionate is a substrate of CYP3A4, the primary enzyme responsible for its hepatic metabolism. Because the total body clearance of fluticasone propionate approaches hepatic blood flow (~1.1 L/min), co-administration with strong CYP3A4 inhibitors can dramatically increase systemic exposure. This is the single most important drug interaction concern with inhaled fluticasone propionate. No other clinically significant drug interactions have been identified.
Monitoring
-
Lung Function
Baseline, 1–3 months, then every 3–12 months
Routine Spirometry (FEV1, PEF) to confirm treatment response. Step down ICS dose after 3 months of well-controlled asthma per GINA guidelines. -
Growth (Paediatric)
Every 6–12 months
Routine Routine stadiometry in children on ICS therapy. Growth velocity reduction of ~0.7 cm/year was observed with FP 100 mcg BID in the 52-week Flovent Rotadisk growth study. Use lowest effective dose to minimise growth impact. -
Oropharyngeal Health
Each visit
Routine Inspect for oral candidiasis (white patches, sore throat). Reinforce mouth rinsing after each inhalation. Treat with topical antifungals if needed. -
HPA Axis Function
If on high-dose ICS or with symptoms of adrenal insufficiency
Trigger-based Morning serum cortisol or ACTH stimulation test if using ≥440 mcg BID chronically or if patient reports fatigue, weakness, hypotension. Essential during transition from systemic corticosteroids. -
Bone Mineral Density
Consider for long-term high-dose ICS in high-risk patients
Trigger-based DEXA scan for postmenopausal women, elderly, patients on concurrent oral steroids, or those with major osteoporosis risk factors. Supplement calcium and vitamin D if at risk. -
Ocular Health
Consider periodic ophthalmology review with long-term ICS
Trigger-based Long-term ICS use is associated with posterior subcapsular cataracts and glaucoma. Refer patients with visual changes or known risk factors. FDA PI recommends close monitoring. -
Inhaler Technique
Each visit
Routine Verify shake-prime-coordinate-rinse sequence for MDI, or correct DPI inhalation technique. Consider spacer device for patients with poor hand-breath coordination.
Contraindications & Cautions
Absolute Contraindications
- Primary treatment of status asthmaticus or acute asthma episodes requiring intensive measures
- Hypersensitivity to fluticasone propionate or any excipient
Relative Contraindications (Specialist Input Recommended)
- Active pulmonary tuberculosis: ICS may worsen TB infection; use only with appropriate anti-TB therapy under specialist guidance
- Untreated systemic fungal, bacterial, viral, or parasitic infections: Immunosuppressive effects of corticosteroids may exacerbate active infections
- Ocular herpes simplex: Corticosteroids may worsen herpetic eye disease
- Concurrent use of strong CYP3A4 inhibitors (ritonavir, ketoconazole): Risk of systemic corticosteroid toxicity
Use with Caution
- Hepatic impairment: Fluticasone is cleared hepatically; impaired liver function may increase systemic exposure. Monitor for signs of hypercorticism
- Recent chickenpox or measles exposure in unimmunised patients: Risk of more severe or fatal illness; consider prophylaxis with VZIG or IG
- Patients transferring from systemic corticosteroids: Risk of adrenal insufficiency; taper systemic steroids slowly while monitoring
- Elderly patients on multiple corticosteroid formulations: Cumulative steroid burden may increase risk of cataracts, glaucoma, osteoporosis, and adrenal suppression
Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to inhaled corticosteroids. After withdrawal from systemic steroids, recovery of HPA axis function may require several months. Patients previously on 20 mg/day or more of prednisone (or equivalent) are at greatest risk. During this transition, patients may need supplementary systemic steroids during periods of physiologic stress (surgery, trauma, severe illness) and should carry a steroid warning card.
Patient Counselling
Purpose of Therapy
Fluticasone propionate is a controller medication that reduces inflammation in the airways over time. It does not provide immediate relief during an asthma attack — a rescue inhaler (such as salbutamol/albuterol) should always be available for that purpose. When taken regularly as prescribed, fluticasone propionate reduces the frequency of asthma symptoms, nighttime awakenings, and asthma attacks. Maximum benefit may take 1–2 weeks to develop, so it is important not to stop using it because it does not seem to work immediately.
How to Take
For MDI (Flovent HFA): Shake the inhaler well before each use. Prime by spraying 4 times into the air before first use or if not used for more than 7 days. Breathe out fully, place the mouthpiece in your mouth, press down on the canister while breathing in slowly and deeply. Hold your breath for up to 10 seconds, then breathe out normally. Wait about 30 seconds between puffs if taking more than one. After finishing, rinse your mouth with water and spit it out — do not swallow. For DPI (Diskus/RespiClick): Do not shake. Exhale away from the device, then inhale forcefully and deeply through the mouthpiece. Rinse mouth afterwards.
Sources
- Flovent HFA (fluticasone propionate inhalation aerosol) prescribing information. GlaxoSmithKline. Revised 01/2019. FDA Label Primary source for all dosing, adverse reaction Table 1 data, contraindications, CYP3A4 interaction data, and growth suppression findings.
- Flovent Diskus (fluticasone propionate inhalation powder) prescribing information. GlaxoSmithKline. Revised 2016. FDA Label Source for DPI-specific adverse reaction data and oral steroid-sparing trial results in severe asthma.
- Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH). N Engl J Med. 2007;356(8):775–789. DOI Landmark 3-year COPD outcomes trial (N=6,112); established pneumonia risk with ICS use and informed off-label COPD prescribing decisions.
- Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial (START). Lancet. 2003;361(9363):1071–1076. DOI While studying budesonide, this trial established the principle of early ICS intervention that applies to all ICS agents including fluticasone propionate.
- Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med. 2004;170(8):836–844. DOI GOAL study demonstrating that guideline-defined asthma control can be achieved in most patients using fluticasone propionate alone or with salmeterol.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 update. GINA Current international asthma guidelines defining ICS dose classifications (low/medium/high) for fluticasone propionate and step therapy approach.
- National Asthma Education and Prevention Program (NAEPP). 2020 Focused Updates to the Asthma Management Guidelines. 2020. NHLBI US asthma guideline update incorporating ICS-formoterol as-needed strategies and step therapy recommendations relevant to fluticasone propionate positioning.
- Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050. DOI Comprehensive review of ICS pharmacokinetics comparing fluticasone propionate with budesonide and other agents; key source for relative potency and pulmonary residence time data.
- Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996;97(1 Pt 2):169–176. DOI Early review establishing the mechanistic basis for fluticasone propionate’s high receptor binding affinity and anti-inflammatory potency relative to older ICS agents.
- Mackie AE, McDowall JE, Falcoz C, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1996;41(6):539–542. DOI Definitive IV PK study establishing Vd (318 L), clearance (1.1 L/min), and terminal half-life (7.8 h) used in the ADME table.
- Falcoz C, Oliver R, McDowall JE, et al. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39 Suppl 1:9–15. DOI Confirmed negligible oral bioavailability (<1%) of fluticasone propionate; critical for understanding that systemic effects arise from pulmonary absorption.
- Thorsson L, Edsbacker S, Kallen A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52(5):529–538. DOI Comparative PK study establishing device-dependent systemic bioavailability: ~13% (Diskus) and ~21% (pMDI) for fluticasone propionate.